2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4685 Variation in transfusion practices in patients with sickle cell disease hospitalized for acute pain: A secondary analysis of the start trial

Noor Alzraikat, MD, Afshin Heidari2, Dunia Hatabah, MD3, Rawan Korman, MD4, Fahd Ahmad, MD5, Gladstone Airewele, MD6, Bolanle Akinsola, MD7, Nitya Bakshi, MBBS, MS8, David C. Brousseau, MD9, Kathleen Brown, MD10, Andrew Campbell, MD11, T. Charles Casper, PhD12, Todd P Chang, MD13, Corrie E. Chumpitazi, MD, MC14, Daniel Cohen, MD15, Keli D. Coleman, MD16, Laura Covelo, NP-C17, Andrea T. Cruz, MD, MPH18, Christopher Clement Denton, MD, MS19, Angela Ellison, MD20, Melanie Fields, MD, MSCI21, Hailey Jensen22, Sara Leibovich, MD23, Derek Meyer24, Chris A. Rees, MD, MPH25, Allison Remiker, MD26, Nidhi V. Singh, MD27, Alexis A. Thompson, MD MPH28, Elliott P. Vichinsky, MD29, Anthony Villella, MD30, Hagar Wilkinson, PharmD31, Bridget Wynn, MD32, Carlton Dampier, MD33, Claudia Morris, MD34
1 Emory University, Atlanta, United States
2 Emory University, Atlanta, United States
3 Emory University, Atlanta, United States
4 Emory University, Atlanta, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Texas Children’s Hospital and Baylor College of Medicine,, Houston, Texas, United States
7 Emory University, Atlanta, United States
8 Yale School of Medicine, New Haven, Connecticut, United States
9 Nemours Children's Health Delaware and the Sidney Kimmel Medical College at Thomas Jefferson University, Wilmington, Delaware, United States
10 Children's National Hospital, Washington, United States
11 Children's National Hospital, Washington, United States
12 University of Utah School of Medicine, Salt Lake City, Utah, United States
13 Children’s Hospital Los Angeles and Keck School of Medicine of the University of Southern California, Los Angeles, California, United States
14 Duke University School of Medicine, Durham, North Carolina, United States
15 Nationwide Children’s Hospital, Columbus, Ohio, United States
16 Medical College of Wisconsin and Children’s Wisconsin, Milwaukee, Wisconsin, United States
17 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
18 Texas Children’s Hospital and Baylor College of Medicine,, Houston, Texas, United States
19 Seattle Children's Hospital, Seattle, Washington, United States
20 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
21 Washington University School of Medicine, St. Louis, Missouri, United States
22 University of Utah School of Medicine, Salt Lake City, Utah, United States
23 University of California, San Francisco, California, United States
24 University of Utah School of Medicine, Salt Lake City, Utah, United States
25 Emory University, Atlanta, United States
26 Medical College of Wisconsin and Children’s Wisconsin, Milwaukee, Wisconsin, United States
27 Texas Children’s Hospital and Baylor College of Medicine,, Houston, Texas, United States
28 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
29 UCSF-Benioff Children's Hospital, Oakland, California, United States
30 Nationwide Children’s Hospital, Columbus, Ohio, United States
31 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
32 Emory University, Atlanta, United States
33 Emory University, Atlanta, United States
34 Emory University, Atlanta, United States

Background

Red blood cell (RBC) transfusion is a common intervention for acute complications of sickle cell disease (SCD), including acute chest syndrome (ACS) and severe anemia. Transfusion practices are not standardized in sickle cell disease (SCD). Understanding practice variations across sites may help to standardize care and improve outcomes.

Methods

We performed a planned secondary analysis of the Sickle Cell Disease Treatment with Arginine Therapy (STArT), a multicenter phase randomized controlled trial of intravenous arginine versus placebo in children and young adults (3–21 years) with SCD requiring parenteral opioids for acute pain. Participants were enrolled at 10 academic Children’s Hospitals including 9 PECARN (Pediatric Emergency Care Applied Research Network) sites between May 2022 and June 2024. Baseline characteristics, transfusion practices, and clinical outcomes were compared between transfused and non-transfused participants. Univariable and multivariable logistic regression identified factors associated with transfusion.

Results

Among 271 participants, 63 (23.2%) received RBC transfusion. Transfused participants more frequently had HbSS genotype (90.5% vs. 64.4%, P<0.001), history of prior transfusion (90.0% vs. 66.0%, P<0.001), history of ACS (83.9% vs. 68.9%, P=0.023), lower hemoglobin in the emergency department (ED) at presentation (8.2 vs. 9.4 g/dL, P<0.001), higher reticulocyte counts and bilirubin levels, and greater oxygen desaturation and supplemental oxygen use in the ED. During their current admission, they had higher rates of ACS (54.0% vs. 10.1%, P<0.001), longer hospitalization (median 138.5 vs. 69.8 hours, P<0.001), longer time to crisis resolution (median 96.0 vs. 56.1 hours, P<0.001), greater opioid use, and more frequent respiratory support (as defined by oxygen use) and antibiotic administration. Mean hemoglobin for the transfused cohort increased from 6.8 to 8.6 g/dL after transfusion (mean increase 1.76 g/dL, 95% CI 1.36–2.15; P<0.001). ACS was the most common indication for transfusion (54.0%), followed by severe anemia (30.2%) and chronic transfusion therapy (27.0%). Among participants with ACS, 63.0% received transfusion. Transfusion practices varied substantially across institutions, with site-specific transfusion rates ranging from 0% to 58.8%. Mean pre-transfusion hemoglobin thresholds varied from 6.6 to 7.6 g/dL, and median time to transfusion also varied (median 2 days, IQR [1–4]). In multivariable analysis, lower presenting hemoglobin (OR 0.59, 95% CI 0.45–0.75; P<0.001) and supplemental oxygen use in the ED (OR 2.60, 95% CI 1.11–6.06; P=0.027) independently predicted transfusion. ACS fell out of the model.

Conclusions

Nearly one-quarter of children and young adults with SCD hospitalized with acute pain received RBC transfusion, most commonly for ACS. Lower presenting hemoglobin and supplemental oxygen use independently predicted transfusion while ACS did not. Marked variation in transfusion frequency, timing, and hemoglobin thresholds was observed across centers. These findings provide a multicenter benchmark of pediatric transfusion practice in patients with SCD and acute pain. Variations in transfusion practice require further investigation.

Noor Alzraikat, MD: No relevant conflicts of interest to declare.